The role of PLGA TPGS nanoparticle on xylazine-ketamine anesthetic activity in male albino rabbits

الملخص EN

D-ɑ-tocopheryl polyethylene glycol succinate (vitamin E TPGS or TPGS) has been approved by food and drug administration (FDA) as harmless adjuvant and is largely used in drug systems delivery.

the aim of the study was to use the tpgs polymer as a drug release model to regulate the release of the anesthetic xylazine-ketamine in order to minimize therapeutically reference dose, avoid side effects, and improve efficacy.

the study performed on 15 adult local breed male rabbits, divided into 3 groups with same number which injected intramuscularly with single dose of suggested anesthetics.

heart rate, respiratory rate, degree of muscle relaxation, onset of action and stages of anesthesia were evaluated, also induction of anesthesia, surgical anesthesia and recovery time were recorded.

nanoprecipitation technique was optimal method for preparing small particle size as well as reduce dose for therapeutic effect.

small and large dose was showed perfect analgesic and muscle relaxant activity of xylazine-ketamine drugs.

ketamine 30 mg and xylazine 10 mg loaded PLGA showed elevation of conciseness period as well as increase muscle relaxant.

ketamine 30 mg and xylazine 10 mg loaded PLGA reduce heart rate but onset of action delayed when compared with reference drug.

the process of nanoprecipitation was ideal for forming small particle sizes and reducing the dosage for therapeutic effects.

PLGA loaded with ketamine-xylazine demonstrated improved cycle concentration (walk time) as well as improved muscle relaxant, finally the protocol created an excellent anesthetic combination for induction of general anesthesia.